Chronic Pouchitis News Today

Full Year Reported Revenue Growth of +12.8%; Core Revenue Growth of +3.5% at Constant Exchange Rate Driven by Growth & Launch Products; Reported EPS Growth of +38.8% Achieved Core Operating... | May 11, 2023

1. In this randomized controlled trial, vedolizumab induced remission in patients with chronic pouchitis after undergoing ileal pouch-anal anastomosis (IPAA) for ulcerative colitis as compared to a placebo. 2. The incidence of overall and severe adverse events was comparable between groups. Evidence Rating Level: 1 (Excellent) Study Rundown: Restorative proctocolectomy with IPAA is routinely performed

−The Phase 4 EARNEST Study Met Its Primary Efficacy Endpoint of Remission of Chronic or Recurrent Pouchitis at Week 14, with 31% of Participants Receiving Vedolizumab Achieving Remission versus... | March 30, 2023